Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013

  • Marc H V Van Regenmortel


A workshop entitled: “What type of HIV Vaccine research should be promoted” took place during a virology conference held in Baltimore in November 2013. The purpose of this workshop was to discuss new paradigms that better fit our increased knowledge of HIV immunopathology and which could possibly be more helpful in guiding future vaccine research than did past unsuccessful approaches. Panelists were asked to respond to four questions regarding possible novel paradigms that could guide future HIV vaccine research and their responses are summarized.


HIV vaccines Paradigms Reverse vaccinology Antibody maturation Immunogenicity Tat vaccine Research funding 


  1. Bachler BC, Humbert M, Palikuqi B, Siddappa NB, Lakhashe SK, et al. Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol. 2013;87:4403–16.CrossRefGoogle Scholar
  2. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34:269–80.CrossRefGoogle Scholar
  3. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2:706–13.CrossRefGoogle Scholar
  4. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12:396–407.CrossRefGoogle Scholar
  5. Bush V. Science, the endless frontier: a report to the president on a program for hostwar scientific research. Washington, DC: National Science Foundation; 1945.CrossRefGoogle Scholar
  6. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med. 1999;5:643–50.CrossRefGoogle Scholar
  7. Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, et al. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Mauritian Cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol. 2010;84:8953–8.CrossRefGoogle Scholar
  8. Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs. 2010;2:347–56.CrossRefGoogle Scholar
  9. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One. 2010;5:e13540.CrossRefGoogle Scholar
  10. Esparza J. The global HIV vaccine enterprise. Int Microbiol. 2005;8:93–101.PubMedGoogle Scholar
  11. Esparza J. A brief history of the global effort to develop an HIV vaccine. Vaccine. 2013a;31:3502–18. Scholar
  12. Esparza J. What has 30 years of HIV research taught us? Vaccine. 2013b;1:513–26.CrossRefGoogle Scholar
  13. Hacking I. Representing and intervening. Princeton, NJ: Cambridge University Press; 1983. p. 1–304.CrossRefGoogle Scholar
  14. Karlsson-Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol. 2008;6:143–55. Scholar
  15. Kuhn TS. The structure of scientific revolutions. Chicago, IL: University of Chicago Press; 1962. p. 1–264.Google Scholar
  16. Lu W, Chen S, Lai C, Guo W, Andrieu J-M. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep. 2012;2:1736–46. Scholar
  17. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33:542–54.PubMedPubMedCentralGoogle Scholar
  18. Mokyr J. The gifts of Athena. Princeton, NJ: Princeton University Press; 2002a. 359 p.Google Scholar
  19. Mokyr J. Technology and the problem of human knowledge. In: The gifts of Athena. Historical origins of the knowledge economy. Princeton: Princeton University Press; 2002b. p. 1–27.Google Scholar
  20. Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, et al. HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes with neutralization by anti-HIV antibodies. PLoS One. 2012;7:e48781.CrossRefGoogle Scholar
  21. Stokes DE. Pasteur’s quadrant. Basic science and technological innovation. Washington, DC: Brooking Institution Press; 1997. p. 1–196.Google Scholar
  22. Van Regenmortel MHV. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine. 2011a;29:7875.CrossRefGoogle Scholar
  23. Van Regenmortel MHV. Limitations to the structure-based design of HIV-1 vaccine immunogens. J Mol Recognit. 2011b;24:741–53.CrossRefGoogle Scholar
  24. Van Regenmortel MHV. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol. 2012a;157:1–20.CrossRefGoogle Scholar
  25. Van Regenmortel MHV. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012b;3:194. Scholar
  26. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature. 2010;464:224–31.Google Scholar
  27. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013;27:F13–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Marc H V Van Regenmortel
    • 1
  1. 1.School of BiotechnologyUniversity of StrasbourgIllkirchFrance

Personalised recommendations